Useful For
Suggests clinical disorders or settings where the test may be helpful
Useful For
Suggests clinical disorders or settings where the test may be helpful
Evaluation of renal tubular damage
Monitoring exposure to cadmium and mercury
Method Name
A short description of the method used to perform the test
Method Name
A short description of the method used to perform the test
AutomatedChemiluminescentImmunometricAssay
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Yes
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Beta-2 Microglobulin, U
Aliases
Lists additional common names for a test, as an aid in searching
Aliases
Lists additional common names for a test, as an aid in searching
Beta 2 Microglobulin Test
Beta-2 Microglobulin, Urine
B2M, (Beta-2 Microglobulin) Urine
Specimen Type
Describes the specimen type validated for testing
Specimen Type
Describes the specimen type validated for testing
Urine
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Patient Preparation: For 12 hours before specimen collection, do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.
Supplies: Sarstedt 5 mL Aliquot Tube (T914)
Container/Tube: Plastic, urine tube
Specimen Volume: 3 mL
Collection Instructions:
1. Patient should empty bladder.
2. Have patient drink at least 0.5 liters of water.
3. Within 1 hour, collect a random urine specimen.
4. Add 1 M sodium hydroxide (NaOH) as preservative to the collection. This preservative is intended to achieve a pH of between approximately 6 and 8.
Forms
If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory
1 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Specimen with pH <6 | Reject |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Urine | Frozen (preferred) | 14 days | |
| Refrigerated | 48 hours |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Useful For
Suggests clinical disorders or settings where the test may be helpful
Evaluation of renal tubular damage
Monitoring exposure to cadmium and mercury
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Beta-2 microglobulin is a low-molecular-weight protein that forms the light chain component of class I histocompatibility (HLA: human leukocyte antigen) antigens.
Increased urine levels are seen in proximal tubular renal damage due to a variety of causes, including cadmium, mercury, lithium, or aminoglycoside toxicity; pyelonephritis; and Balkan nephropathy, a chronic interstitial nephritis of unknown etiology.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
< or =300 mcg/L
Interpretation
Provides information to assist in interpretation of the test results
Interpretation
Provides information to assist in interpretation of the test results
Increased excretion is consistent with renal tubular damage.
Beta-2 microglobulin excretion is increased 100 to 1000 times normal levels in cadmium-exposed workers.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Degradation of beta-2 microglobulin occurs at pH <6.0.
Clinical Reference
Recommendations for in-depth reading of a clinical nature
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Ikeda M, Ezaki T, Tsukahara T, et al: Threshold levels of urinary cadmium in relation to increases in urinary beta2-microglobulin among general Japanese populations. Toxicol Lett. 2003 Feb 3;137(3):135-141
2. Moriguchi J, Ezaki T, Tsukahara T, et al: Comparative evaluation of four urinary tubular dysfunction markers, with special references to the effects of aging and correction for creatinine concentration. Toxicol Lett. 2003 Aug 28;143(3):279-290
3. Stefanovic V, Cukuranovic R, Mitic-Zlatkovic M, Hall PW: Increased urinary albumin excretion in children from families with Balkan nephropathy. Pediatr Nephrol. 2002 Nov;17(11):913-916
Method Description
Describes how the test is performed and provides a method-specific reference
Method Description
Describes how the test is performed and provides a method-specific reference
Testing is performed on the Immulite 2000. The Immulite 2000 Beta-2 Microglobulin assay is a solid phase, 2-site chemiluminescent enzyme-labeled immunometric assay. The solid-phase bead is coated with an affinity-purified murine monoclonal anti-beta-2 antibody. The serum sample and alkaline phosphatase conjugated affinity-purified goat polyclonal anti-beta-2 antibody are incubated to bind beta-2 microglobulin into an antibody sandwich complex.
The chemiluminescent substrate, a phosphate ester of adamantyl dioxetane, in the presence of alkaline phosphatase produces light proportional to the concentration of the beta-2 microglobulin in the sample.(Package insert: IMMULITE 2000 Beta-2 Microglobulin. Siemens Healthcare Diagnostics; 11/05/2012)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
No
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday, Wednesday, Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
1 to 3 days
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
3 months
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Rochester
Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
82232
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| B2MU | Beta-2 Microglobulin, U | 1953-9 |
| Result Id | Test Result Name | Result LOINC Value Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure. |
|---|---|---|
| B2MU | Beta-2 Microglobulin, U | 1953-9 |
FAQs
What is the normal range of B2M in urine? ›
Normal findings : Blood: 0.70-1.80 mcg/mL. Urine: ≤300 mcg/L.
What is a beta-2 microglobulin test for urine? ›What is a beta-2 microglobulin tumor marker test? A beta-2 microglobulin tumor marker test measures the amount of a protein called beta-2 microglobulin (B2M) in your body fluids. The test usually uses a sample of your blood. It may also be done using urine (pee) or in rare cases cerebrospinal fluid (CSF).
What is considered a high B2M level? ›High B2M levels (>2.9 mg/dl) could identify a group of patients with an adverse outcome within patients in stage I disease (P = 0.02).
What is beta-2 microglobulin B2M indicative in case of? ›For the diagnosis of multiple myeloma, the serum β2-microglobulin level is one of the prognostic factors incorporated into the International Staging System. The serum β2-microglobulin level is elevated (>2.7 mg/L) in 75% of patients at the time of diagnosis. Patients with high values have inferior survival.
What is too high beta-2 microglobulin? ›What does it mean if your Beta-2 Microglobulin, Serum result is too high? Elevated concentration levels of beta-2 microglobulin is attributed to diseases with a high cell turnover. It is a powerful prognosis factor for multiple myeloma, a type of bone marrow cancer.
What is the beta-2 microglobulin level for multiple myeloma? ›The International Staging System for Multiple Myeloma
Stage 1 – Serum beta-2 microglobulin level measuring less than 3.5 (mg/L) with an albumin level measuring 3.5 (g/dL) or greater.